Title:
CD3 HUMANIZED ANTIBODY AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/135536
Kind Code:
A1
Abstract:
The present invention relates to a CD3 humanized antibody and an application thereof, and disclosed are a humanized antibody or an antigen-binding fragment that specifically binds to a CD3ε subunit, a multi-specific antigen-binding molecule, a nucleic acid fragment, a carrier, a host cell, a preparation method, a pharmaceutical composition, a pharmaceutical use, and a treatment method for cancer or tumors, infectious diseases or autoimmune diseases. In addition, the present invention is extremely important for the development of CD3 antibody drugs and cell therapy drugs.
Inventors:
WEI PEIPEI (CN)
GE HU (CN)
GE HU (CN)
Application Number:
PCT/CN2021/140901
Publication Date:
June 30, 2022
Filing Date:
December 23, 2021
Export Citation:
Assignee:
JIANGSU SIMCERE PHARM CO LTD (CN)
International Classes:
C07K16/00; A61K39/00; A61K39/395; A61P31/00; A61P35/00; C07K16/28
Foreign References:
| CN111183153A | 2020-05-19 | |||
| CN111247171A | 2020-06-05 | |||
| US20200377594A1 | 2020-12-03 | |||
| CN111454357A | 2020-07-28 | |||
| US20080025975A1 | 2008-01-31 | |||
| US20070224191A1 | 2007-09-27 |
Attorney, Agent or Firm:
BEIJING HUIZHENG LAW OFFICE (CN)
Download PDF: